Using droplet digital PCR (ddPCR) techniques, Liebs et al. [13] found out that the detection of common KRAS and BRAF point mutations in plasma was only sporadically successful in the cohort of stage I–III CRC patients; however, 68% of the patients with distant metastasis demonstrated the presence of mutations in cfDNA. This evidence concerns the gene BRAF and colorectal carcinoma.